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Analgesic tolerance of opioid agonists in mutant
mu-opioid receptors expressed in sensory
neurons following intrathecal plasmid gene
delivery
Guangwen Li1†, Fei Ma1,2†, Yanping Gu1 and Li-Yen Mae Huang1*
Abstract
Background: Phosphorylation sites in the C-terminus of mu-opioid receptors (MORs) are known to play critical roles
in the receptor functions. Our understanding of their participation in opioid analgesia is mostly based on studies of
opioid effects on mutant receptors expressed in in vitro preparations, including cell lines, isolated neurons and brain
slices. The behavioral consequences of the mutation have not been fully explored due to the complexity in studies
of mutant receptors in vivo. To facilitate the determination of the contribution of phosphorylation sites in MOR to
opioid-induced analgesic behaviors, we expressed mutant and wild-type human MORs (hMORs) in sensory dorsal
root ganglion (DRG) neurons, a major site for nociceptive (pain) signaling and determined morphine- and the full
MOR agonist, DAMGO,-induced effects on heat-induced hyperalgesic behaviors and potassium current (IK)
desensitization in these rats.
Findings: A mutant hMOR DNA with the putative phosphorylation threonine site at position 394 replaced by an
alanine (T394A), i.e., hMOR-T, or a plasmid containing wild type hMOR (as a positive control) was intrathecally
delivered. The plasmid containing GFP or saline was used as the negative control. To limit the expression of
exogenous DNA to neurons of DRGs, a neuron-specific promoter was included in the plasmid. Following a plasmid
injection, hMOR-T or hMOR receptors were expressed in small and medium DRG neurons. Compared with saline or
GFP rats, the analgesic potency of morphine was increased to a similar extent in hMOR-T and hMOR rats. Morphine
induced minimum IK desensitization in both rat groups. In contrast, DAMGO increased analgesic potency and elic-
ited IK desensitization to a significantly less extent in hMOR-T than in hMOR rats. The development and extent of
acute and chronic tolerance induced by repeated morphine or DAMGO applications were not altered by the T394A
mutation.
Conclusions: These results indicate that phosphorylation of T394 plays a critical role in determining the potency of
DAMGO-induced analgesia and IK desensitization, but has limited effect on morphine-induced responses. On the
other hand, the mutation contributes minimally to both DAMGO- and morphine-induced behavioral tolerance.
Furthermore, the study shows that plasmid gene delivery of mutant receptors to DRG neurons is a useful strategy
to explore nociceptive behavioral consequences of the mutation.
Keywords: Opioid tolerance, Opioid receptors, T394A mutation, Dorsal root ganglion, Nociception, Plasmid
DNA injection
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Background
Morphine is one of the most frequently used analgesic
opioids used in clinics for the treatment of severe acute
and chronic pain. Its use is often limited by a reduced
effectiveness to elicit pain relief following repeated use
i.e., tolerance. As the result of the involvement of com-
plex molecular events, the mechanisms underlying mor-
phine tolerance in vivo remain unclear. Nearly all the
opioids used in clinics, including morphine and fentanyl,
exert their analgesic effects through the activation of
mu-opioid receptors (MORs). Once activated by opioids,
the MOR undergoes G-protein receptor kinase (GRK)-
dependent phosphorylation. Within minutes of agonist
exposure, MOR starts to lose coupling with its effectors,
including adenylyl cyclase, G protein-coupled inwardly
rectifying potassium (GIRK) channels and voltage
dependent Ca2+ channels, and reduces its agonist sensi-
tivity, a phenomenon referred to as “desensitization”
[1,2]. Following the removal of agonists, MOR quickly
resensitizes and dephosphorylates. After a long (hrs to
weeks) opioid exposure, however, MOR desensitization
becomes enhanced and receptor-mediated resensitiza-
tion impaired. MOR loses its responsiveness to agonists
and gives rise to tolerance [1-3]. Since MOR phosphoryl-
ation plays such important roles in the development of
sensitization and tolerance, attempts have been made to
study the effects of serine and threonine phosphorylation
in the C-terminus of MORs on receptor signaling using
phosphorylation deficient S375A and T394A mutant
MORs. In contrast to wild-type MORs, phosphorylation
of T394A mutant human MORs (hMORs) expressed
in Chinese hamster ovary (CHO) cells induced by the
full opioid agonist, [D-Ala2-MePhe4-Gly-ol] enkephalin
(DAMGO), is much reduced, and DAMGO-induced in-
hibition of adenylyl cyclase activity is also decreased
[4,5]. Furthermore, the T394A rat MORs expressed in
neuroblastoma cells showed faster internalization and
rapid resensitization [6]. Similarly, morphine-induced de-
sensitization was blocked in S375A-expressed HEK cells
[7]. Thus, phosphorylation of T394 and S375 in MORs is
critical in MOR sensitization, internalization and resensiti-
zation. Most of our understanding of desensitization and
tolerance development are based on the studies of opioid
actions in model cells or in tissues isolated from chronic
opioid treated animals. Behavioral consequences of the
mutation have not been studied extensively. Recently,
S375A MOR knock-in mice were produced [8]. Behavioral
tolerance was assessed in the mutant mice. Morphine-
induced tolerance was found not to be affected by S375A
mutation. Although elegant, the approach is labor intensive
and time consuming. To find a simpler way to facilitate the
determination of behavioral consequences of specific phos-
phorylation sites in MORs that may play a major role in
the pain signal transmission, we intrathecally applied
T394A MOR plasmid DNA to express mutant hMORs in
sensory DRG neurons, which participate in the transmis-
sion of nociceptive information. The nociceptive behavioral
consequences of mutant hMOR expression were then ex-
amined. This study allowed us to determine if such an ap-
proach can efficiently screen the properties of mutant
receptors and assess the role of mutation sites in the func-
tion of receptors.
Results
Expression of hMOR-T and hMOR in DRG neurons through
direct plasmid injection
To express mutant hMORs in DRGs, the hMOR-T
(100 μg/25 μl) plasmid was slowly injected intrathecally
through a syringe at the L4-5 vertebra level using the
modified direct transcutaneous intrathecal method [9].
For positive control, hMOR plasmid was injected instead.
For negative control, a GFP plasmid or saline vehicle was
injected. No signs of adverse effects of the injection in the
test animals were observed.
We first determined the functional consequence of the
injection of hMOR-T or hMOR plasmid by studying the
effects of morphine on thermal nociceptive responses. The
development of analgesic effect of morphine was exam-
ined (Figure 1). Following an intrathecal injection of one
dose of morphine (4 μg/10 μl), the paw withdrawal latency
(PWL) of the rat hindpaw in response to heat stimulation
was measured every 15 min for 120 min. The analgesic ef-
fect was observable 15 min after the injection, reached a
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Figure 1 Time course of morphine-induced analgesia. A dose of
morphine (4 μg/10 μl) was given at time 0 (arrow) and PWLs
expressed in (% MPE) in response to heat stimuli were measured at
various intervals. The analgesia was observed within 15 min of
morphine application and reached its maximum level at 30 min. The
analgesia was gradually decreased and dissipated >100 min later.
The MPEs obtained from hMOR-T and hMOR rats were significantly
higher than that of saline rats (*p < 0.05, n = 5-7). The differences in
MPEs between hMOR-T and hMOR rats were not significant.
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peak level ~30 min and started to decay at 45 min after
the morphine application. The PWLs gradually returned
to the baseline level 90–120 min later. Morphine analgesia
developed in a similar manner in all three rat groups ex-
cept that the peak analgesia was significantly higher in
hMOR-T and hMOR rats than in saline rats. In the sub-
sequent experiments, unless specified, morphine effects
were studied 30 min after its injection.
To confirm hMOR-T and hMOR expression in DRGs,
rats that had undergone the behavioral studies were
fixed and DRGs extracted. The level of exogenously
expressed hMOR-T or hMOR in L4-5 DRGs was studied
immunohistochemically using a monoclonal mouse anti-
HA antibody, which recognized the HA epitope fused to
the N terminus of hMOR-T and hMOR.
No HA labeled neurons were detected in the saline rat
group. In contrast, 30-31% of DRG neurons were brightly
labeled in hMOR-T and hMOR rat groups (Figure 2). Ten
to eleven percent of the labeled cells were small diameter
(d) (d < 25 μm) and 18-19% of them were medium size
(25 ≤ d < 35 μm) DRG neurons (Table 1). Very few large
neurons were labeled. The level of HA expression and the
distribution of the expression among different size neu-
rons were almost identical in the hMOR-T and hMOR rat
groups. Since HA labels were not found in satellite glial
cells, the neuron-specific endolase (NSE) or synapsin pro-
moter incorporated in our plasmids effectively limited the
hMOR or hMOR-T expression to neurons. Endogenous
MORs, labeled with anti-MOR antibody, were found in
29 ± 4.5% of DRG small and medium size neurons (data
not shown). Thus, plasmid injection substantially in-
creased the level of MORs expressed in DRGs.
Morphine analgesia is enhanced in hMOR and hMOR-T rats
The dose-responses of morphine in the four rat groups (sa-
line, GFP, hMOR-T, hMOR, 5–7 rats for each group) were
determined by examining the PWLs in the presence of dif-
ferent doses of i.t. morphine. One or two concentrations of
morphine were studied in one experimental session. When
two doses of morphine were tested, a cumulative morphine
dose–response protocol with a starting dose and a fixed
interval [10] was used. For instance, an initial dose of i.t.
morphine, e.g., 0.1 μg/10 μl, was applied. Thirty minutes
later, the PWL was measured and a second dose of i.t.
morphine, e.g., 1 μg/10 μl was administered and measured
after a 30 min wait. Rats were then returned to their cages
to recover. Three days later, a second set of i.t morphine
dosages, e.g., 0.3 and 3 μg/10 μl, were studied. Since the
two morphine doses used in one experiment differed by 10
fold, the cumulative effect between two morphine applica-
tions was not significant. The dose–response curves ob-
tained could well be fitted by the Hill equation and the
effective doses (ED50) were obtained (Figure 3).
To make sure that plasmid itself did not produce non-
specific effects on morphine responses, we compared the
morphine dose–response in rats injected with GFP plas-
mid with those injected with saline. The dose–response
curves obtained from GFP and saline rat groups were al-
most identical. The ED50 of morphine was 3.23 μg/10 μl
for GFP rats and 3.86 μg/10 μl for saline rats (Figure 3A).
Thus, the changes in morphine dose-responses produced
by MOR or MOR-T plasmid were not a result of unspe-
cific effects of plasmid injection. The ED50 of morphine
for hMOR-T (1.08 μg/10 μl) and ED50 for hMOR
hMOR hMOR-TSaline
Figure 2 Expression of HA in DRG neurons following i.t. injection of hMOR-T or hMOR plasmids. HA immunostaining in DRG sections
isolated from rats injected with saline, hMOR or hMOR-T plasmids. Bright HA immunofluorescence was observed in DRG neurons of both hMOR
and hMOR-T injected rat groups. No HA labels were found in neurons of saline injected rats. Scale bars, 50 μm.
Table 1 HA-labeled hMOR and hMOR-T expressed in
different sized DRG neurons
Small cell Medium cell Large cell Total†
d* < 25 μm 25 < d < 35 μm d > 35 μm
Saline 0 0 0 0
hMOR 9.71 ± 0.66 18.22 ± 1.83 1.82 ± 0.24 29.75
hMOR-T 11.08 ± 0.17 19.14 ± 1.86 0.45 ± 0.45 30.67
Total number of cells counted as 100%; all values are HA-labeled cells
expressed as % of counted cells. Values are means ± SE; 3 rats in each
rat group.
*d: cell diameter. †Total: total percentage, including small, medium and large
cells, of HA-labeled cells.
There were no significant differences between hMOR and hMOR groups in all
sizes of DRG neurons.
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(1.38 μg/10 μl) rats were similar (Figure 3B). Both were
significantly lower than the ED50 for saline or GFP rats.
Morphine was therefore much more potent in producing
analgesia in plasmid-injected rats.
Morphine-induced tolerance
It has been shown that hMOR-T abolishes MOR phos-
phorylation, thus the DAMGO-induced desensitization of
MOR [4,5]. It was therefore of interest to determine if this
cellular change in MOR function results in any changes in
morphine-induced behavioral tolerance. We first deter-
mined the acute tolerance by applying a high dose (30 μg/
10 μl) of i.t. morphine and measuring PWLs on thermal
stimuli. Eighteen hours later, the response to a second
dose (30 μg/10 μl) of morphine was again measured. The
morphine response was significantly reduced (Figure 4A).
The extent of decrease was similar among hMOR-T,
hMOR and saline rat groups. Thus, T394A mutation did
not affect morphine-induced acute tolerance.
We then examined morphine-induced chronic toler-
ance in the three rat groups. Intrathecal morphine
(1.5 μg/10 μl for hMOR-T and hMOR rats and 5.0 μg/μl
for saline rats) was applied twice daily. The specific mor-
phine doses were chosen to produce ~50% of the max-
imum possible effect (MPE) in respective rat groups.
The first dose of morphine was given in the morning
and the analgesic effect was subsequently measured. The
second dose of morphine was given in the afternoon and
rats were returned to cages. The dosing regiment was re-
peated for 5 consecutive days. The morphine analgesic
effects were diminished rapidly with repeated morphine
applications. The rates of decrease were similar among
three rat groups. Thus, the upregulation of MORs and
mutation of T394A altered neither the development
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Figure 3 Dose–response of morphine on PWLs in hMOR-T, hMOR and saline or GFP rats. Different doses of morphine were given in 10 μl
volume and the PWL responses were determined 30 min after each morphine application. The solid lines were the theoretical fit of the data
using the Hill equation. A. The Hill coefficient (h) was 1.01 for GFP and 1.09 for saline rats. Morphine ED50 (μg/10 μl) was 3.23 ± 0.49 for GFP and
3.86 ± 0.53 for saline rats. (B) The h was 0.94 for hMOR-T, 1.02 for hMOR. The morphine ED50 was 1.08 ± 0.08 for hMOR-T, 1.38 ± 0.07 for hMOR.
The apparent morphine affinities of hMOR-T and hMOR rats were significantly higher than that of saline or GFP rats.
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Figure 4 Acute and chronic morphine behavioral tolerance in hMOR-T and hMOR rats are the same. A. Acute tolerance was assessed by
measuring changes in morphine analgesia induced by a high dose (30 μg/10 μl) of morphine given 18 hrs earlier. On day 2, the three rat groups
exhibited a similar extent of reduction in morphine responses (saline: 41.4%, n = 4; hMOR: 40.4%, n = 3; hMOR-T: 43.3%, n = 3). B. Chronic
morphine tolerance was studied in rats subjected to morphine treatment (hMOR-T: 1.5 μg/10 μl, n = 8; hMOR: 1.5 μg/10 μl, n = 4; saline:
5.0 μg/10 μl, n = 4) twice daily for 5 consecutive days. The chronic morphine-induced tolerance developed quickly and the rates of development
among the rat groups were similar.
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nor the extent of morphine-induced chronic tolerance
(Figure 4B).
Differences and similarities between DAMGO- and
morphine-induced analgesia
Since the properties of opioid-induced analgesia often
depends on the agonist used, the dose–response and toler-
ance of the full-agonist, DAMGO, in hMOR and hMOR-
T rats were also studied. The development of analgesic
effect of DAMGO is shown in Figure 5A. Compared with
morphine, DAMGO was faster acting. The analgesic effect
of DAMGO reached a peak level ~15 min after application
and dissipated 60 min later. In the subsequent experi-
ments, DAMGO effects were measured 15 min after its
injection.
The dose–response curves for DAMGO were fit with
the Hill equation (Figure 5B). The ED50 of DAMGO
was 0.15 μg/10 μl for hMOR rats, 0.38 μg/10 μl for
hMOR-T rats and 0.66 μg/10 μl for GFP rats. The ED50
for hMOR-T was 2.53 fold larger than that for hMOR.
This is in contrast with morphine ED50, which had no
statistic difference between hMOR-T and hMOR rat
groups (Figure 3).
Acute and chronic DAMGO-induced behavioral toler-
ance were also examined (Figure 6). We applied 4 μg/
10 μl i.t. DAMGO to hMOR and 8 μg/10 μl to hMOR-T
rats, which produced 88.6% and 87.1% MPE respectively.
The same strength of second dose DAMGO was applied
to each rat group 18 hrs later and behavioral responses
were examined. Similar extent reduction of DAMGO re-
sponses in two rat groups was observed (Figure 6A). To
examine DAMGO-induced chronic tolerance, 4 μg/10 μl
or 8 μg/10 μl of DAMGO was applied to the hMOR or to
hMOR-T rat group respectively twice daily and analgesic
effects were measured after the 1st dose agonist applica-
tion. The rate of development and the extent of tolerances
between hMOR and hMOR-T groups in response to
DAMGO application were very similar (Figure 6B). Thus,
T394A mutation had no effect on DAMGO-mediated
acute and chronic tolerance.
To determine if the T394 site is important for MOR
desensitization in DRG neurons, the amplitudes of agonist-
induced outward IK were measured during continued
presence of DAMGO or morphine (Figure 7). DAMGO in-
duced robust desensitization of IK in both hMOR and
hMOR-T expressed DRG neurons. Compared with hMOR-
expressed DRG neurons, the extent of DAMGO-induced
IK desensitization in hMOR-T neurons was reduced. Thus,
phosphorylation of the T394 site is important for full
agonist-induced IK desensitization in DRGs. Morphine-
induced IK desensitization was also studied. In contrast to
DAMGO, morphine induced minimum IK desensitization
in DRG neurons isolated from hMOR and hMOR-T rats
(Figure 7). Phosphorylation of the T394 site does not ap-
pear to affect morphine-induced IK desensitization.
Discussion
The purposes of this study are to determine (1) if the
T394 site in MORs is involved in opioid tolerance and (2)
if the application of DNA plasmids to upregulate receptors
is a feasible way to study behavioral consequences of the
expression of mutant receptors in sensory neurons. Viral
vectors and mutant mice are two approaches commonly
used to alter receptor expression. Aside from the concerns
of the toxicity of viral vectors and possible compensatory
adaptations in mutant mice, those approaches are com-
plex. We sought a simpler method to accomplish the goal.
Using hMOR as an example, we introduced mutant
hMOR-T and hMOR into L4-L5 DRGs by intrathecal in-
jection of DNA plasmid. A neuron-specific promoter was
used to limit exogenous hMOR expression in neurons
(Figure 2). Receptor upregulation could be seen within
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Figure 5 Time course and dose response of DAMGO in hMOR-T and hMOR rats. (A) DAMGO (3 μg/10 μl) was given at time 0 (arrow) and
PWLs were measured at various intervals. The DAMGO induced analgesia developed quickly, reached a maximum ~15 min and the response
returned to the baseline ~ 60 min later. (B) The DAMGO ED50 (μg/10 μl) obtained from dose–response analyses were 0.15 ±0.02 ((hMOR),
0.38 ± 0.08 (hMOR-T) and 0.66 ± 0.13 (GFP). The Hill coefficients were 0.6 for hMOR, 0.6 for hMOR-T and 0.7 for GFP.
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3 days following the plasmid injection. The expression of
hMOR-T and hMOR were found in small and medium
DRG neurons which are known to mediate nociception.
The time course of morphine effect was not altered by the
mutation (Figure 1). Compared with GFP-injected rats,
the upregulation resulted in 3.0- and 2.3-fold increase in
morphine potency in hMOR-T and hMOR rat groups re-
spectively (Figure 3), a magnitude analogous to that ob-
served in DRGs transduced with adeno-associated viral
vector (AAV) expressing MORs [11]. We showed here
that the development of acute and chronic morphine be-
havioral tolerance is independent of the phosphorylation
of T394 in MOR (Figure 4), a result similar to the findings
obtained in S375A MOR mutant mice [8]. Thus, phos-
phorylation of the single site, i.e., T394 in hMORs, is not
sufficient to alter the tolerance effect of morphine in vivo.
Even though our plasmid injection resulted in a substan-
tial increase in the expression of hMORs in DRG neurons
(Figure 2), one needs to ascertain that similar reduction in
the morphine ED50 and identical morphine-induced toler-
ance observed in hMOR and hMOR-T DRG neurons were
not a result of endogenous rat MORs masking morphine
effects in the T394 mutant. The studies were therefore
repeated using the full agonist, DAMGO. We found
that DAMGO ED50 (Figure 5) and DAMGO-evoked IK
desensitization (Figure 7) in hMOR and hMOR-T DRGs
are significantly different. Thus, T394 is important in de-
termining DAMGO affinity and desensitization. The ob-
servations also suggest that the expression of hMOR-T in
DRGs was sufficiently large to exhibit its opioid agonist-
dependent responses. Since the development and extent
of DAMGO-induced tolerance were similar in hMOR and
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Figure 6 hMOR-T and hMOR exhibit similar acute and chronic DAMGO-induced behavioral tolerance. (A) Acute tolerance. On day 1, 4 μg
DAMGO produced 88.6% MPE in hMOR rats and, 8 μg DAMGO produced 87.1% MPE in hMOR-T rats. On day 2, similar reduction in DAMGO
responses (hMOR: 39.4%, hMOR-T: 44.4%, n = 5-7) were observed. (B) Chronic tolerance was obtained by applying 4 μg/10 μl DAMGO to hMOR
and 8 μl/10 μl to hMOR-T twice daily for 4 consecutive days. The rates and extents of DAMGO-induced tolerance developed similarly in hMOR
and hMOR-T rat groups.
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hMOR-T neurons (Figure 6), as observed in morphine-
induced tolerance (Figure 4), T394 in the hMOR appears
to play a limited role in opioid-dependent tolerance.
Birdsong et al. [12] reported that prolonged treatment
of cells with high-efficacy agonists, which causes MOR
desensitization, increases the agonist affinity for MOR.
In our study of opioid dose–response relation in hMOR
and hMOR-T, DRGs were exposed to agonists longer
than 15–30 min. Thus, the dose–response curves were
obtained under desensitization conditions. We found
that DAMGO had a lower affinity for hMOR-T than
that for hMOR (Figure 5), a result consistent with the
observation that DAMGO induced less desensitization
in hMOR-T cells (Figure 7).
The advantage of our approach includes that DNA plas-
mids are easy to produce. With proper promoter design,
the mutant receptors expression can be targeted to spe-
cific cell types (Figure 2). In contrast to the long waiting
period (> 3 weeks) for viral vector-induced expression of
mutant MORs, the expression reaches its peak level within
3 days of plasmid injection. Using a slow rate of intra-
thecal plasmid injection procedure (see Methods), the ex-
pression of mutant MORs can be largely confined within
L4-6 DRGs. It has been well documented that DNA plas-
mids are seldom incorporated into the genome, have low
immunogenicity and rarely produce ill effects in host ani-
mals [13]. There are a couple of noticeable limitations to
the plasmid injection approach. One is that the expression
level of mutant receptors is maintained for a short period.
Following a single injection of i.t. hMOR-T or hMOR, the
enhancing effect was reduced by 40% in ten days and dis-
sipated in fourteen days. It has been shown that two injec-
tions of anti-inflammatory cytokine IL-10 DNA would
prime immune responses and result in long term (up to
90 days) upregulation of IL-10 [13,14]. Unlike the immune
mediators, double injections of mutant MOR DNA did
not lengthen the duration of the expression (unpublished
observation). Nevertheless, the expression of exogenous
receptors could be maintained at a steady level following
repeated injections of the DNA plasmid every seven
days (data not shown). Another possible limitation is that
changes induced by the mutant MOR have to be suffi-
ciently large to overcome the influence of endogenous
MORs. Since the differences in DAMGO ED50 and IK
desensitization in hMOR-T and hMOR DRGs were readily
observed (Figures 5 and 7), changes in opioid responses
induced by mutant hMORs are likely to be detected under
our experimental conditions.
We and others have found that the mutation of a single
phosphorylation site, i.e., T394 or S375, was not sufficient
to alter chronic behavioral tolerance (Figures 4 and 6) [8].
It is of interest to determine if phosphorylation of other or
multiple sites in MOR would alter morphine tolerance.
In addition to T394 and S375, a number of serine and
threonine sites, e.g., T357, S363 and T370, have been local-
ized in the C-terminus of MOR [15-17]. In model cells,
these sites were found to be phosphorylated by different ki-
nases. In a mass spectrometric analysis phosphorylation of
the T394 site was not detected [15]. This result is inconsist-
ent with the observation that DAMGO-induced phosphor-
ylation of T394A mutant receptors is much reduced [4,18].
Additional studies are needed to resolve the inconsistency.
The consequences of the phosphorylation of serine and
threonine sites in receptor desensitization have been exten-
sively studied in vitro. The opioid-induced desensitization
was found to diminish in T394A and S375A mutant recep-
tors [4,6,7,18]. Furthermore, the mechanism underlying re-
ceptor desensitization depends on the agonist used [19-21].
In locus ceruleus neurons, morphine-induced desensi-
tization was shown to depend on PKC whereas DAMGO-
induced desensitization is mediated by GRK2 and
independent of PKC [20]. It is suggested that DAMGO-
and morphine-bound MORs assume differential confor-
mations that are targeted by different GRKs to give rise to
various efficiencies in receptor internalization [16,21,22]
and changes in the responses to PKC [23]. We also found
that IK desensitization in hMOR expressing DRG neurons
depends on opioid agonists. T394 mediates DAMGO-
induced desensitization, but does not affect morphine
action on IK (Figure 7). The mechanism underlying the
agonist-dependent desensitization and its effect on opioid-
induced analgesic behaviors have yet to be explored.
The relationship between MOR desensitization and
cellular tolerance has been studied in cells or slices ob-
tained from chronic morphine treated animals [2]. Cellu-
lar tolerance was defined as a sustained decrease in the
morphine efficacy for its coupling effector, e.g., GIRK
channels [24] or as right-shift in the morphine dose–re-
sponse curve [25]. Cellular tolerance and desensitization
were found to be separate processes that occur simultan-
eously [24] and β-arrestin2 was shown to impair the
MOR resensitization and recycling [25,26]. The relation-
ship between cellular and behavioral tolerance is not en-
tirely clear. The information will be essential for our
understanding of the mechanisms underlying behavioral
tolerance. Using our approach, the behavioral tolerance
of various mutants can be determined and its relation-
ship with cellular tolerance and desensitization assessed.
This knowledge will be useful in designing ways to im-
prove morphine usage in clinics.
Conclusions
Using a plasmid to deliver mutant T394A hMOR to DRG
neurons, we showed that the T394 site mediates DAMGO-
induced IK desensitization and alters DAMGO potency for
hMOR while it does not affect morphine-induced re-
sponses. Furthermore, phosphorylation of the T394 site
had a limited role in the development of DAMGO- and
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morphine-induced tolerance. More important, the study
demonstrates that nociceptive behavioral consequence of
mutations in receptors can be efficiently studied by plas-
mid gene delivery of mutant receptors to sensory neurons.
Methods
Animals
Experiments were performed on adult (200–250 g) male
Spargue Dawley rats. All experimental procedures were
approved by the Institutional Animal Care and Use Com-
mittee at the University of Texas Medical Branch and
were in accordance with the guidelines of the National In-
stitutes of Health and of the International Association for
the Study of Pain (IASP).
Plasmid preparation
The N-terminus HA epitope (YPYDVPDYA) tagged wild-
type human mu opioid receptor (hMOR) plasmid and the
point mutant (T394A) of the HA tagged hMOR plasmid
(hMOR-T) used in this study were gifts from Dr. J.B.
Wang, University of Maryland, Baltimore, MD. To pro-
duce plasmids containing either of the opioid receptor
genes under the control of an neuron-specific endolase
(NSE) or synapsin promoter, the PCR products of the
hMOR-T and of hMOR were prepared and ligated into
the pTR-NSE or -synapsin plasmid as described [27].
To upregulate MORs in rat DRGs, the hMOR-T
(100 μg) plasmid was suspended in a 25 μl sterile su-
crose (3%)-containing Dulbecco’s phosphate-buffered sa-
line [14] and injected intrathecally through a syringe at
the L4-L5 vertebra level using the modified direct trans-
cutaneous intrathecal method [9]. The plasmid solution
was slowly injected within 5 seconds and the needle
stayed for another 5 seconds before removal. In some
experiments, a second dose of intrathecal plasmid was
administered two days later. For controls, hMOR, GFP
or saline vehicle was injected.
Behavioral experiments
The opioid-agonist induced analgesic effects on thermal
hyperalgesia to radiant heat in different rat groups were
assessed as described [27]. To obtain consistent behav-
ioral responses, rats were acclimated in Plexiglass boxes
placed on the test platform for 30 minutes per day for
3 days prior to experiments. For morphine or DAMGO
applications, a PE-10 catheter was placed between the
vertebrae S1 and S2 with its tip extended rostrally to the
vertebrae L4-L5 under sodium pentobarbital anesthesia.
To measure PWLs, radiant heat was placed under the
plantar surface of the hind paw and the time elapsed
from the onset of radiant heat stimulation to the with-
drawal of the hind paw was recorded. The heat intensity
was adjusted to give a baseline latency around 10s; a cut-
off time of 30s was set to prevent possible tissue damage.
To obtain baseline PWLs, three measurements separated
by a 5-min interval were made for the rat’s hindpaw and
scores were averaged.
Two days after the last plasmid injection, a PWL was
determined prior to morphine or DAMGO administra-
tion. To determine the time course of opioid agonist ef-
fects, a dose of i.t. agonist was given and the withdrawal
latencies were measured at various time points later. To
determine the dose-dependent effect of an agonist on
PWLs, either one or two doses of the agonist was used.
When a cumulative agonist dose–response protocol [10]
was used, an initial dose of i.t. agonist was given. The
withdrawal threshold was measured 15 (for DAMGO) or
30 min (for morphine) later. A second dose of agonist
was then applied and PWLs were measured.
Immunohistochemistry
Rats were perfused with 4% paraformaldehyde and 0.2%
picric acid fixative within 2 days after the end of the be-
havioral study. L4, L5 DRGs were removed, sectioned
(10 μm) and washed with phosphate buffer saline (PBS).
The sections were incubated with a PBS solution contain-
ing 10% normal goat serum and 0.2% Triton X-100 for
60 minutes to block non-specific binding. To detect ex-
ogenously expressed hMOR-T or hMOR receptors, sec-
tions were incubated with a monoclonal mouse anti-HA
antibody (1:1000, Sigma, St. Louis, MO) diluted in a 0.2%
TritonX-100 PBS plus 4% normal goat serum at 4°C over-
night. In control staining, the primary antibody was omit-
ted. The primary antibody was removed by rinsing the
tissue sections in the PBS solution for 5 minutes × 3 times.
The sections were then incubated with the secondary
antibody, Alexa Fluor 546 goat anti-mouse IgG (1:200,
Molecular Probes, Carlsbad, CA) in 0.2% Triton-X PBS
plus 4% normal goat serum, at room temperature for
1 hour. The sections were washed 5 minutes × 3 times
and mounted with mount medium (Vector Laboratories,
Burlingame, CA). Labeled cells from fifteen tissue sections
obtained from each rat were counted and results from 3
rats in each rat group, i.e., hMOR-T, hMOR, saline rats,
were analyzed. MetaMorph offline software was used for
digital image data analysis.
Opioid tolerance
Morphine- and DAMGO-induced tolerances were studied
by determining PWLs following repeated applications of
morphine. Baseline PWLs were first determined prior to
the application of an opioid agonist. Acute tolerance was
determined by measuring changes in analgesia following
two high dose of agonist treatments applied within
18 hours. For chronic tolerance studies, opioid agonist
was i.t. injected twice a day (once in the morning and once
in the afternoon). Thermal-induced PWLs were assessed
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following the morning morphine dosing. The procedure
was repeated for 4–5 days.
Whole cell patch clamp recordings
Outward IK were recorded from small or medium (15–
30 μm in diameter) acutely dissociated DRG neurons
isolated from 25–35 old male rats using the described
method [28,29]. Briefly, L4-L5 DRGs were excised from
anesthetized rats 3–5 days after plasmid injection and put
in an ice-cold oxygenated dissecting solution. It contained
(in mM) 135 NaCl, 5 KCl, 2 KH2PO4, 1.5 CaCl2, 6 MgCl2,
10 glucose and 10 HEPES, pH 7.2 (osmolarity, 305 mos-
mol/liter). After removal of the connective tissue sur-
rounding the ganglia, the tissue was put into a dissecting
solution containing papain (20 unit/ml, Worthington Bio-
chemical, Lakewood, MJ) and collagenase D (1 mg/ml,
Roche Applied Science, Indianapolis, IN) and incubated at
37°C for 50 min. After the incubation period, DRGs were
removed from the enzyme solution, washed and placed
into a fresh dissecting solution. Cells were then dissociated
by trituration with fire-polished glass pipets and placed on
glass coverslips. After a resting period (~ 2 h), a glass
coverslip was put in the recording chamber and cells were
superfused at room temperature with an external solution
containing (in mM) 130 NaCl, 5 KCl, 2 KH2PO4, 2.5
CaCl2, 1 MgCl2, 10 HEPES, 10 glucose, pH 7.3; osmolarity,
295–300 mosmol/liter). During agonist application, the
external solution containing a MOR agonist will be ap-
plied to the recorded cell through an electronic valve.
Patch-clamp electrodes were filled with an internal solu-
tion, containing (in mM) 115 K-gluconate, 10 NaCl, 10
EGTA, 2 CaCl2, 1.5 Na-ATP, 0.3 GTP, 10 glucose and 10
HEPES and had a resistance of 3–5 Mohm. The currents
were filtered at 5 kHz and sampled at 1 msec/pt using a
Dagan amplifier. Current responses were analyzed using
Igor Pro software.
Membrane potential was held at −60 mV. IK responses
were evoked by stepping from −60 mV to 0 mV and out-
ward currents were recorded. Desensitization of IK was
quantified by measuring changes in peak outward K+
currents during a prolonged application of a MOR agon-
ist. The change in IK was expressed as the percentage
change of the initial peak response.
Data analyses
All data were recorded as mean ± SEM. Analgesic effects
were shown as MPE by using the relation MPE = (post-
drug PWL - baseline PWL) / (cutoff PWL - baseline
PWL) × 100%. To assess the significance of changes be-
tween two means, the Student’s t test was used. The
time course and chronic tolerance of morphine effects
were analyzed by two-way ANOVA with repeated mea-
sures followed by post-hoc Bonferroni analysis. Dose–re-
sponse curve was plotted as MPE vs morphine dose and
fitted with the Hill equation, i.e., response =min + (max −
min) * [dosen(dosen + ED50n)] where min and max are
minimal and maximal responses, the potency, ED50, is the
effective morphine dose producing 50% of the maximal
analgesic effect, and n is the Hill coefficient. A P < 0.05
was considered significant.
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